US 12,435,127 B2
Therapeutic neutralization antibodies for the treatment of peanut allergy
Sarita U. Patil, Newton, MA (US); Wayne G. Shreffler, Beverly, MA (US); and John Christopher Love, Somerville, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Appl. No. 17/762,902
Filed by The General Hospital Corporation, Boston, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
PCT Filed Sep. 25, 2020, PCT No. PCT/US2020/052875
§ 371(c)(1), (2) Date Mar. 23, 2022,
PCT Pub. No. WO2021/062268, PCT Pub. Date Apr. 1, 2021.
Claims priority of provisional application 62/905,698, filed on Sep. 25, 2019.
Prior Publication US 2022/0348643 A1, Nov. 3, 2022
Int. Cl. C07K 16/16 (2006.01); A61P 37/00 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/16 (2013.01) [A61P 37/00 (2018.01); G01N 33/6854 (2013.01); C07K 2317/21 (2013.01); C07K 2317/30 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
 
1. An isolated antibody that binds to Ara h 2 (conglutin-7), or an antigen-binding fragment thereof, wherein the antibody comprises the following six CDRs:
(a) an CDR-H1 comprising the amino acid sequence of GFTFRDYS (SEQ ID NO: 21);
(b) an CDR-H2 comprising the amino acid sequence of IRFDGTTK (SEQ ID NO: 22);
(c) an CDR-H3 comprising the amino acid sequence of AKDNGWRAFDH (SEQ ID NO: 23);
(d) an CDR-L1 comprising the amino acid sequence of QSLLHRNGYIY (SEQ ID NO: 24);
(e) an CDR-L2 comprising the amino acid sequence of FVS (SEQ ID NO: 25); and
(f) an CDR-L3 comprising the amino acid sequence of MQALETPWT (SEQ ID NO: 26).